Results 171 to 180 of about 118,583,499 (297)

Factors Associated With Challenging Behaviour in People With Severe‐Profound Intellectual Disabilities: A Systematic Review

Journal of Intellectual Disability Research, EarlyView.
ABSTRACT Background Individuals with severe to profound intellectual disability (ID) exhibit high support needs and significant communication impairments and may present with challenging behaviours such as aggression, self‐injury and stereotypies. These behaviours can cause distress, hinder healthcare access and delivery and impair quality of life for ...
I. D. C. van Balkom, J. Cooke, A. G. de Cuba, E. Burkitt‐Wright, C. Gaasterland, M. Burdeus‐Olavarrieta   +5 more
wiley   +1 more source

Antifibrinolytic therapy for preventing VWD-related postpartum hemorrhage: indications and limitations

Blood Advances, 2017
Peter A. Kouides
doaj   +1 more source

Concizumab for the management of heavy menstrual bleeding in a woman with mild hemophilia A. [PDF]

Res Pract Thromb Haemost
Mizoguchi Y, Shimomura M, Teraoka Y, Fujii T, Okada S.   +4 more
europepmc   +1 more source

Plasma ADAMTS13 activity in healthy dogs and dogs with chronic enteropathy

Journal of Small Animal Practice, EarlyView.
Objectives A disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13 is a von Willebrand factor cleaving enzyme that is associated with prothrombotic/hypercoagulable states in humans. In people, A disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13 activity is reduced with inflammatory bowel disease ...
S. I. Barth, S. M. DeMonaco, B. J. Conner, P. B. S. Serpa, A. R. Wilkinson   +4 more
wiley   +1 more source

Oral Soft Tissue Biopsy in Patients Receiving Direct Oral Anticoagulants: A Prospective Cohort Study on Bleeding Outcomes

Oral Diseases, EarlyView.
ABSTRACT Background Direct oral anticoagulants (DOACs) are the first‐line therapy for stroke prevention in non‐valvular atrial fibrillation and venous thromboembolism. While evidence supports their continuation during routine dental procedures such as tooth extractions, data on oral soft tissue biopsies remain limited.
Rossana Izzetti, Chiara Cinquini, Antonio Barone, Marco Nisi   +3 more
wiley   +1 more source

Characterization of a mouse model to study mechanisms of hemophilia A pain. [PDF]

Blood Adv
Fouda R, Argueta D, Goel Y, Velasco G, O'Daniel K, Peterson K, Zamora Z, Joseph BC, von Drygalski A, Gupta K.   +9 more
europepmc   +1 more source

An In Vitro Study Simulating Prophylactic Anticoagulation in Haemophilia A and B

eJHaem, Volume 7, Issue 6, December 2026.
ABSTRACT Introduction Patients with haemophilia A (HA) and haemophilia B (HB) are at increased bleeding risk. A recent guidance document suggests considering pharmacological thromboprophylaxis on a case‐by‐case basis in these patients undergoing surgery at high‐risk of venous thromboembolism.
Nicoletta Riva, Kevin Vella, Kieron Hickey, Nigel Debattista, Carmel Grima, Denise Borg‐Aquilina, Liberato Camilleri, Jiong Jiong Guo, Alexander Gatt   +8 more
wiley   +1 more source

Cardiovascular risk scores estimate arterial thrombotic risk in aging adults with hemophilia in the ADVANCE Japan cohort. [PDF]

Blood Adv
Nagao A, Sawada A, Kanematsu T, Yamasaki N, Takedani H, Nojima M, Hiroi Y, Fujii T, Suzuki N, Matsushita T, Higasa S, Amano K, Chikasawa Y.   +12 more
europepmc   +1 more source

Determinants of Immune Tolerance Induction Outcomes in 237 Persons With Severe Hemophilia A

European Journal of Haematology, Volume 117, Issue 5, Page 1292-1300, November 2026.
ABSTRACT Immune tolerance induction (ITI) to eradicate an immune response against factor VIII (FVIII) has been used in hemophilia A (HA) with various success rates, costs, and treatment burden. The present study aimed to identify markers predictive of ITI success.
Marcus Fager Ferrari, Josefin Roslund, Eric Manderstedt, Erik Berntorp, Jan Astermark, Malmö and Hemophilia Inhibitor Genetics Study Investigators   +5 more
wiley   +1 more source

Discovery and development of a bispecific antibody for the treatment of hemophilia. [PDF]

Proc Natl Acad Sci U S A
Pao W.
europepmc   +1 more source